Mutant herpes simplex virus-mediated suppression of retinoblastoma

Current Eye Research

Volumn 18, Issue 5, 1999, Pages 321-326

  Kogishi, Jun Ichi ^a   Miyatake, Shin Ichi ^a   Hangai, Masanori ^a   Akimoto, Masayuki ^a   Okazaki, Kazushiro ^a   Honda, Yoshihito ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Gene therapy; Herpes simplex virus; Lytic infection; Retinoblastoma; Ribonucleotide reductase

Indexed keywords

BETA GALACTOSIDASE; TRYPAN BLUE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HERPES SIMPLEX VIRUS; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RETINOBLASTOMA; TUMOR VOLUME; VIRUS INFECTION; VIRUS MUTANT;

ANIMALS; BETA-GALACTOSIDASE; CELL SURVIVAL; HISTOCYTOCHEMISTRY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; RETINAL NEOPLASMS; RETINOBLASTOMA; SIMPLEXVIRUS; TUMOR CELLS, CULTURED;

EID: 0032937318     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.18.5.321.5354     Document Type: Article

References (26)

1. Shields JA, Shields L. Current management of retinoblastoma. Mayo Clin Proc. 1994;69:50-56.
2. Lueder GT, Judisch FG, O'Gorman TW. Second non-ocular tumors in survivors of heritable retinoblastoma. Arch Ophthalmol. 1986;104:372-373.
3. The Committee for the National Registry of Retinoblastoma. Survival rate and risk factors for patients with retinoblastoma in Japan. Jpn J Ophthalmol. 1992;36:121-131.
4. Markert JM, Coen DM, Malick A, Mineta T, Martuza RL. Expanded spectrum of viral therapy in the treatment of nervous system tumors. J Neurosurg. 1992;77:590-594.
5. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (Washington DC) 1991;252:854-856.
6. Skinner GRB, Cowan M, Davies J, Brookes K, Billstrom M, Buchan A. Reduced tumorigenicity of rodent tumour cells and tumour explants following infection with wild type and mutant herpes simplex virus, bovine mammillitis virus and encephalomyocarditis virus. Br J exp Path. 1988;69:495-504.
7. Brandt CR, Imesch PD, Robinson NL, Syed NA, Untawale S, Darjatmoko SR, Chappell RJ, Heinzelman P, Albert DM. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virol. 1997; 229:283-291.
8. Thelander L, Reichard P. Reduction of ribonucleotide. Annu Rev Biochem; 1979;48:133-158.
9. Brandt CR, Kintner RL, Pumfery AM, Visalli RJ, Grau DR. The herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol 1991;72: 2043-2049.
10. Brandt CR, Spencer B, Imesch P, Garneau M, Deziel R. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob Agents Chemother 1996;40:1078-1084.
11. Liuzzi M, Deziel R, Moss N, Beaulieu P, Bonneau A, Bousquet C, Chafouleas JG, Garneau M, Jaramillo J, Krogsrud RL, Lagoce L, McCollum RS, Nawoot S, Guindon Y. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature (London) 1994;372:695-698.
12. Yamada Y, Kimura H, Morishima T, Daikoku T, Maeno K, Nishiyama Y. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis. 1991;164: 1091-1097.
13. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 1988;62:196-205.
14. Nicolo M, Chiocca EA. Marker gene transfer and oncolysis of human Y79 retinoblastoma cells mediated by herpes simplex virus mutants. Ophthalmic Research. 1998;30:30-36.
15. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1995; 1:938-943.
16. Boviatsis EJ, Chase M, Wei MX, Tamiya T, Hurford RK Jr, Kowall NW, Tepper RI, Breakefield XO, Chiocca EA. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther. 1994;5:183-191.
17. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg. 1996;224:323-329.
18. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using gancyclovir-hypersensitive ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54:3963-3966.
19. Carroll NM, Chase MBA, Chiocca EA, Tanabe KK. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res. 1997;69:413-417.
20. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther. 1997;8:2057-2068.
21. Yoon SS, Chase MBA, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg. 1998;228:366-374.
22. Chou J, Kern ER, Whitey J, Roizman B. Mapping of herpes simplex virus -1 neurovirulence to g 34.5, a gene nonessential for growth in culture. Science. 1990;250: 1262-1266.
23. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, Whiteley R. Comparison of genetically engineered herpes simplex virus for the treatment of brain tumors in a scid mouse model of human glioma. Proc Natl Acad Sci USA. 1995;92:1411-1415.
24. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997;57:1502-1509.
25. Boviatsis EJ, Park JS, Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO, Chiocca EA. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994;54:5745-5751.
26. Ramakrishnan R, Fink DJ, Guihua J, Desai P, Glorioso J, Levine M. Competitive quantitative polymerase chain reaction (PCR) analysis of herpes simplex virus type 1 DNA and LAT RNA I latency infected cells of brain. J Virol. 1994;68: 1864-70.